Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Surgery

Show all topics

DOI

10.1016/s0140-6736(19)33008-9

Other Formats

PDF